Am­gen com­mits to low-cost Repatha; AZTher­a­pies bags Smith Ther­a­peu­tic­s' CAR-Treg tech for neu­roin­flam­ma­tion

→ As Am­gen tracks mod­est growth of its Repatha fran­chise and braces for the ar­rival of cheap­er cho­les­terol-low­er­ing med­i­cines in the mar­ket, its com­mer­cial team …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER